White-coat hypertension: growing evidence in favour of its adverse prognostic significance.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Interpretation of Ambulatory Blood Pressure Monitoring for Risk Stratification in Hypertensive Patients: The 'Ambulatory Does Prediction Valid (ADPV)' Approach.Diagnostics (Basel, Switzerland) · 2023
   Review
2. Brazilian Guidelines of Hypertension - 2020.Arquivos brasileiros de cardiologia · 2021
   Article
3. Hypertension and metabolic disorders, a glance from different phenotypes.American journal of preventive cardiology · 2020
   Review
4. Prognostic role of masked and white-coat hypertension: 10-Year mortality in treated elderly hypertensives.Journal of human hypertension · 2019
   Observational
5. Stress, Genes, and Hypertension. Contribution of the ISIAH Rat Strain Study.Current hypertension reports · 2018
   Review

Corrections and comments

• Comment on
  White-coat hypertension is a risk factor for cardiovascular diseases and total mortality.2017

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as